| BDX |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.18 vs. cons $3.142 |
MEDIUM |
| BDX |
Report |
Revenue |
IN-LINE |
pred ~$4.92B vs. cons $4.890B |
MEDIUM |
| BDX |
Report |
BioPharma Systems revenue |
BEAT |
pred ~$650M vs. cons $637M |
MEDIUM |
| BDX |
Guide |
FY26 adjusted EPS |
BETTER |
guide ~$12.65–$12.85 vs. cons $12.61 |
MEDIUM |
| BDX |
Guide |
FY26 organic revenue growth |
UNCHANGED |
guide low-single-digit vs. cons 2.51% |
MEDIUM |
| BDX |
Guide |
FY26 adjusted operating margin |
UNCHANGED |
guide approximately 25% vs. cons UNVERIFIED |
LOW |
| BDX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
LOW |
| BDX |
Return |
5-day cumulative residual |
+2.0% (STABILIZE) |
STABILIZE — real Q4 EPS upside, moderated by a demanding stock setup |
LOW |